Intravenous (IV) ketamine has been previously used to treat various refractory pain conditions. We present a series of patients with refractory migraine treated with intravenous ketamine in the hospital setting.
Ketamine for the Treatment of Chronic Migraines Read More »
Like many other drugs, ketamine has multiple effects rendering it suitable for various indications including anesthesia, sedation, acute and chronic pain relief and treatment of therapy-resistant depression.
How Ketamine Cures Depression: The Science Behind It Read More »
A single subanesthetic dose of ketamine, an NMDA receptor antagonist, leads to fast-acting antidepressant effects.
Effects of Ketamine on Dendritic Architecture In Vivo in the Mouse Medial Frontal Cortex Read More »
A mind-altering drug called ketamine is changing the way some doctors treat depression.
NPR Report: Ketamine Gains Traction As A Treatment For Depression Read More »
It is either the most exciting new treatment for depression in years or it is a hallucinogenic club drug that is wrongly being dispensed to desperate patients in a growing number of clinics around the country.
Special K, a Hallucinogen, Raises Hopes and Concerns as a Treatment for Depression Read More »
Ketamine, a glutamate N-methyl-D-aspartate (NMDA) receptor antagonist, has shown rapid antidepressant effects, but small study groups and inadequate control conditions in prior studies have precluded a definitive conclusion. The authors evaluated the rapid antidepressant efficacy of ketamine in a large group of patients with treatment-resistant major depression.
Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression Read More »
As converging evidence suggests a role for the glutamate system in the pathophysiology of OCD, we tested whether a single dose of ketamine, a non-competitive N-methyl-D-aspartate (NMDA) glutamate receptor antagonist, could achieve rapid antiobsessional effects.
Ketamine to Treat Obsessive-Compulsive Disorder (OCD) Read More »
Carlos Zarate, M.D., speeds up treatment for major depression at the National Institutes of Health (NIH) Intramural Research Program (IRP). Dr. Zarate is Chief of the Experimental Therapeutics & Pathophysiology Branch and the Section on the Neurobiology and Treatment of Mood Disorders at the National Institute of Mental Health (NIMH).
Ketamine and Depression: From Despair to Hope in Hours Read More »
A notable recent discovery shows that ketamine, a N-methyl-D-aspartate receptor antagonist, produces rapid (within hours) antidepressant responses in patients who are resistant to typical antidepressants.
Yale University School of Medicine: Ketamine for Depression Read More »
Complex Regional Pain Syndrome Type 1 (CRPS-1) responds poorly to standard pain treatment. We evaluated if the N-methyl-D-aspartate receptor antagonist S(+)-ketamine improves pain in CRPS-1 patients.
Ketamine Treats Patients with Complex Regional Pain Syndrome Type 1 Read More »